Use of non-vitamin K antagonist oral anticoagulants in patients with heart failure and atrial fibrillation: does concomitant kidney disease change our practice?

Farhan Shahid¹, Eduard Shantsila¹, Gregory Y H Lip^{1

2}

Affiliations

¹ University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.
² Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Free article

Editorial

Farhan Shahid et al. Eur J Heart Fail. 2016 Sep.

Free article

. 2016 Sep;18(9):1172-4.

doi: 10.1002/ejhf.552.

Farhan Shahid¹, Eduard Shantsila¹, Gregory Y H Lip^{1

2}

¹ University of Birmingham Institute of Cardiovascular Sciences, City Hospital, Birmingham, UK.
² Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

No abstract available

Comment on

Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment.
Hawkins NM, Jhund PS, Pozzi A, O'Meara E, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, Virani S, McMurray JJ. Hawkins NM, et al. Eur J Heart Fail. 2016 Sep;18(9):1162-71. doi: 10.1002/ejhf.614. Eur J Heart Fail. 2016. PMID: 27594177